Beacon Investment Advisory Services Inc. Cuts Stock Position in Eli Lilly and Company $LLY

Beacon Investment Advisory Services Inc. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 10.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,158 shares of the company’s stock after selling 2,342 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Eli Lilly and Company were worth $15,381,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Sumitomo Mitsui Financial Group Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth approximately $27,000. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the second quarter worth $29,000. Steph & Co. boosted its position in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the last quarter. Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company during the second quarter valued at $31,000. Finally, Bare Financial Services Inc increased its holdings in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Guggenheim restated a “buy” rating and set a $1,163.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 3rd. UBS Group reissued a “neutral” rating on shares of Eli Lilly and Company in a research note on Thursday, December 18th. Daiwa America raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 16th. HSBC reaffirmed a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Four analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,155.36.

Eli Lilly and Company Stock Up 0.0%

NYSE:LLY opened at $1,077.26 on Friday. The company has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.70, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a fifty day simple moving average of $986.75 and a 200-day simple moving average of $841.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.